Option chain shows key data for 89bio's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for 89bio.

89bio (NASDAQ:ETNB) Stock, Option Chain

89BIO INC

89bio

89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).

Display,Of,Stock,Market,Quotes

Earnings

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

AGMH

AGRI

BCTX

BTOG

ENPH

ETNB

FRGE

GAIA

GELS

MRIN

NDRA

NTHI

PEGA

SEDG

SNOA

SXTC

Why Vertiv Holdings Shares Are Trading Higher By 17%; Here Are 20 Stocks Moving Premarket

Stock Movers

AKRO

DADA

EVER

HAIN

LGIH

LGTY

PTLO

TITN

TKNO

TREE

Dada Nexus, Titan Machinery, AT&amp;T And Other Big Stocks Moving Higher On Monday

Closeup,Of,Wall,St.,Street,Sign,And,Large,New,York

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Eurozone

ALLK

ELAB

VERU

Nasdaq Dips 3%; Chicago Fed National Activity Index Rises In December

89bio Inc

Press Releases

89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

89bio Provides Business Update and Outlook for 2025

Financing

89bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants

89bio, Inc. Announces Pricing of $250.0 Million Public Offering of Common Stock and Pre-Funded Warrants

89bio Announces Closing of its Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

89bio Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates

89bio to Participate in the Leerink Partners Global Healthcare Conference

89bio Reports First Quarter 2025 Financial Results and Corporate Updates

89bio to Participate in Upcoming Investor Conferences

Ardelyx

CareDx

Celldex Therapeutics, Inc. - Common Stock

Celldex Therapeutics

Centessa Pharmaceuticals plc - American Depositary Shares

Centessa Pharmaceuticals

Dynavax Technologies Corporation - Common Stock

Dynavax Technologies

Dyne Therapeutics

Geron

GRAIL

Gyre Therapeutics

IDEAYA Biosciences

Immunocore Holdings plc - American Depositary Shares

Immunocore Holdings

Iovance Biotherapeutics, Inc. - Common Stock

Iovance Biotherapeutics

Disc Medicine

Janux Therapeutics

MiMedx Group

Mesoblast Limited - American Depositary Shares

Mesoblast

Mineralys Therapeutics, Inc. - Common Stock

Mineralys Therapeutics

MannKind

Novavax

Arcus Biosciences

Syndax Pharmaceuticals, Inc. - Common Stock

Syndax Pharmaceuticals

ARS Pharmaceuticals

Vera Therapeutics, Inc. - Class A Common Stock

Vera Therapeutics

Viridian Therapeutics, Inc. - Common Stock

Viridian Therapeutics

Zymeworks

Goldman Sachs

Citigroup

HC Wainwright & Co.

Cantor Fitzgerald

Comments

89bio

89bio (ETNB) Options

Loading...

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell